Log in to save to my catalogue

Safety and efficacy of factorXIa inhibition with milvexian for secondary stroke prevention (AXIOMATI...

Safety and efficacy of factorXIa inhibition with milvexian for secondary stroke prevention (AXIOMATI...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_334571

Safety and efficacy of factorXIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP) : a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Subjects

More information

Scope and Contents

Contents

Background People with factor XI deficiency have lower rates of is chaemic stroke than the general population and infrequent spontaneous bleeding, suggesting that factor XI has a more important role in thrombosis than in haemostasis. Milvexian, an oral small-molecule inhibitor of activated factor XI, added to standard antiplatelet therapy, might re...

Alternative Titles

Full title

Safety and efficacy of factorXIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP) : a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_gup_ub_gu_se_334571

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_334571

Other Identifiers

ISSN

1474-4422,1474-4465

DOI

10.1016/S1474-4422(23)00403-9

How to access this item